Totalt antall besøk

Visninger
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis113

Totalt antall besøk pr måned

september 2018oktober 2018november 2018desember 2018januar 2019februar 2019mars 2019
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis11557533

Nedlastinger av fil

Visninger
article.pdf35

Visninger pr land

Visninger
United States47
United Kingdom18
Norge17
China11
France6
Canada2
Italy2
Austria1
Australia1
Brazil1

Visninger pr by

Visninger
Ann Arbor33
Southend18
Guangzhou6
Mountain View5
Chengdu2
Houston2
Milan2
Montréal2
Tromsø2
Ashburn1